NCT01965431View on ClinicalTrials.gov

Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Healthy
Interventions
DRUG

BI 207127

Medium dose oral administration

DRUG

BI 207127 placebo

DRUG

Faldaprevir placebo

DRUG

Faldaprevir

Medium dose oral administration

DRUG

Moxifloxacin (Avalox®)

Trial Locations (1)

Unknown

1241.40.1 Boehringer Ingelheim Investigational Site, Ingelheim

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY